SUBCLINICAL MESOTHELIOMA
Clinical trials for SUBCLINICAL MESOTHELIOMA explained in plain language.
Never miss a new study
Get alerted when new SUBCLINICAL MESOTHELIOMA trials appear
Sign up with your email to follow new studies for SUBCLINICAL MESOTHELIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill trial targets early mesothelioma in High-Risk gene carriers
Disease control TerminatedThis study tests an oral drug (decitabine/cedazuridine) in people with BAP1 gene mutations who have early-stage mesothelioma. The goal is to see if the drug can stop the cancer from growing or shrink it. About 9 participants will be enrolled, and the study is currently on hold.
Matched conditions: SUBCLINICAL MESOTHELIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 09:19 UTC
-
Promising mesothelioma drug study halted before it began
Disease control TerminatedThis study aimed to test the drug alrizomadlin (APG-115) in people with a genetic condition called BAP1 cancer syndrome who had early-stage mesothelioma. The goal was to see if the drug could stabilize or improve the disease. However, the study was withdrawn before any participan…
Matched conditions: SUBCLINICAL MESOTHELIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC